Abstract
Mesenchymal stromal cells (MSCs) have been always considered as a useful option for therapeutic purposes. MSCs can be derived from many sources, perhaps one of the most therapeutically valuable sources is the Wharton’s Jelly (WJ), a gelatinous tissue layer found within the umbilical cord that contains myofibroblast-like stromal cells. Previous studies investigating Wharton’s Jelly-derived MSCs reveal that they have more powerful proliferative, immunosuppressive and therapeutic activities compared to MSCs derived from adult bone marrow or adipose tissue. The present review discusses the phenotypic features, potential therapeutic uses and optimization of experimental protocols for WJ-derived stem cells. Previous work show successful results when WJ-MSCs were used as transplantable cells for treatment of various diseases (e.g., cancer, chronic liver disease, cardiovascular diseases, nerve, cartilage, tendon injury and degenerated intervertebral disc). These positive results are attributed to favorable transplantable features the WJ-MSCs display which include ease of sourcing, in vitro expandability, differentiation abilities, immune-evasion and immune-regulation capacities. However, further research work is demanded to harness the benefits of WJ-MSCs into clinical application.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
